Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data

2026-02-12 13:50:41 ET

The last time I spoke about Upstream Bio, Inc. ( UPB ), it was in a Seeking Alpha article entitled " Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study ." With respect to this article, I noted that the company was able to achieve highly competitive data for its thymic stromal lymphopoietin [TSLP] inhibitor Verekitug for the treatment of patients with chronic rhinosinusitis with nasal polyps [CRSwNP]. This was in terms of once every 12 weeks [Q12W] dosing that offered competitive differentiation. Based on this, I had placed a Buy rating on this stock because of it....

Read the full article on Seeking Alpha

For further details see: